CN109497520A - A kind of self-closing disease tailored version clinical nutrition composition and preparation method thereof - Google Patents
A kind of self-closing disease tailored version clinical nutrition composition and preparation method thereof Download PDFInfo
- Publication number
- CN109497520A CN109497520A CN201811361341.6A CN201811361341A CN109497520A CN 109497520 A CN109497520 A CN 109497520A CN 201811361341 A CN201811361341 A CN 201811361341A CN 109497520 A CN109497520 A CN 109497520A
- Authority
- CN
- China
- Prior art keywords
- self
- closing disease
- clinical nutrition
- tailored version
- nutrition composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 68
- 201000010099 disease Diseases 0.000 title claims abstract description 67
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 38
- 230000035764 nutrition Effects 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 24
- 230000035622 drinking Effects 0.000 claims abstract description 16
- 235000008216 herbs Nutrition 0.000 claims abstract description 16
- 230000010354 integration Effects 0.000 claims abstract description 16
- 235000013305 food Nutrition 0.000 claims abstract description 12
- 239000004615 ingredient Substances 0.000 claims abstract description 11
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 10
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 9
- 239000006041 probiotic Substances 0.000 claims abstract description 8
- 235000018291 probiotics Nutrition 0.000 claims abstract description 8
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims description 54
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 24
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 20
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 20
- 241000186000 Bifidobacterium Species 0.000 claims description 13
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 12
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 12
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 12
- 235000010469 Glycine max Nutrition 0.000 claims description 12
- 235000013793 astaxanthin Nutrition 0.000 claims description 12
- 239000001168 astaxanthin Substances 0.000 claims description 12
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 12
- 229940022405 astaxanthin Drugs 0.000 claims description 12
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 12
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 11
- 244000197580 Poria cocos Species 0.000 claims description 11
- 235000008599 Poria cocos Nutrition 0.000 claims description 11
- 235000016998 Ribes burejense Nutrition 0.000 claims description 11
- 241000735566 Ribes burejense Species 0.000 claims description 11
- 150000004676 glycans Chemical class 0.000 claims description 11
- 210000003022 colostrum Anatomy 0.000 claims description 10
- 235000021277 colostrum Nutrition 0.000 claims description 10
- 239000004310 lactic acid Substances 0.000 claims description 10
- 235000014655 lactic acid Nutrition 0.000 claims description 10
- 229960003080 taurine Drugs 0.000 claims description 10
- 239000000049 pigment Substances 0.000 claims description 9
- 235000018102 proteins Nutrition 0.000 claims description 9
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 8
- 241000205585 Aquilegia canadensis Species 0.000 claims description 8
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 8
- -1 K-IAO Chemical compound 0.000 claims description 8
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 235000013406 prebiotics Nutrition 0.000 claims description 8
- 241000196324 Embryophyta Species 0.000 claims description 7
- 229920002774 Maltodextrin Polymers 0.000 claims description 7
- 239000005913 Maltodextrin Substances 0.000 claims description 7
- 229940035034 maltodextrin Drugs 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 244000246386 Mentha pulegium Species 0.000 claims description 6
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 6
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 6
- 240000002547 Rosa roxburghii Species 0.000 claims description 6
- 235000000640 Rosa roxburghii Nutrition 0.000 claims description 6
- 239000005862 Whey Substances 0.000 claims description 6
- 102000007544 Whey Proteins Human genes 0.000 claims description 6
- 108010046377 Whey Proteins Proteins 0.000 claims description 6
- 244000273928 Zingiber officinale Species 0.000 claims description 6
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 6
- 235000014633 carbohydrates Nutrition 0.000 claims description 6
- 235000013350 formula milk Nutrition 0.000 claims description 6
- 235000008397 ginger Nutrition 0.000 claims description 6
- 235000001050 hortel pimenta Nutrition 0.000 claims description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 6
- 244000068988 Glycine max Species 0.000 claims description 5
- 235000001014 amino acid Nutrition 0.000 claims description 5
- 229940024606 amino acid Drugs 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 229920002752 Konjac Polymers 0.000 claims description 4
- 239000005018 casein Substances 0.000 claims description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 4
- 235000021240 caseins Nutrition 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 241000208688 Eucommia Species 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- 229920001503 Glucan Polymers 0.000 claims description 3
- 229920001202 Inulin Polymers 0.000 claims description 3
- 108010001441 Phosphopeptides Proteins 0.000 claims description 3
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims description 3
- 241000219780 Pueraria Species 0.000 claims description 3
- 229920000294 Resistant starch Polymers 0.000 claims description 3
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 3
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 235000020243 first infant milk formula Nutrition 0.000 claims description 3
- 229930003944 flavone Natural products 0.000 claims description 3
- 150000002213 flavones Chemical class 0.000 claims description 3
- 235000011949 flavones Nutrition 0.000 claims description 3
- 235000013312 flour Nutrition 0.000 claims description 3
- 239000003292 glue Substances 0.000 claims description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 3
- 229940029339 inulin Drugs 0.000 claims description 3
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 235000021254 resistant starch Nutrition 0.000 claims description 3
- 239000011435 rock Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 3
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 2
- OPSXJNAGCGVGOG-DKWTVANSSA-L Calcium L-aspartate Chemical compound [Ca+2].[O-]C(=O)[C@@H](N)CC([O-])=O OPSXJNAGCGVGOG-DKWTVANSSA-L 0.000 claims description 2
- 235000002566 Capsicum Nutrition 0.000 claims description 2
- 240000008574 Capsicum frutescens Species 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 2
- 229930064664 L-arginine Natural products 0.000 claims description 2
- 235000014852 L-arginine Nutrition 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- 229930182816 L-glutamine Natural products 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- 102000010445 Lactoferrin Human genes 0.000 claims description 2
- 108010063045 Lactoferrin Proteins 0.000 claims description 2
- 240000003183 Manihot esculenta Species 0.000 claims description 2
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 claims description 2
- 108010073771 Soybean Proteins Proteins 0.000 claims description 2
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 2
- 239000001354 calcium citrate Substances 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- MKJXYGKVIBWPFZ-CEOVSRFSSA-L calcium;(2s)-2-hydroxypropanoate Chemical compound [Ca+2].C[C@H](O)C([O-])=O.C[C@H](O)C([O-])=O MKJXYGKVIBWPFZ-CEOVSRFSSA-L 0.000 claims description 2
- 239000001390 capsicum minimum Substances 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- GRWVQDDAKZFPFI-UHFFFAOYSA-H chromium(III) sulfate Chemical compound [Cr+3].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRWVQDDAKZFPFI-UHFFFAOYSA-H 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 2
- 239000004222 ferrous gluconate Substances 0.000 claims description 2
- 235000013924 ferrous gluconate Nutrition 0.000 claims description 2
- 229960001645 ferrous gluconate Drugs 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 2
- 229940078795 lactoferrin Drugs 0.000 claims description 2
- 235000021242 lactoferrin Nutrition 0.000 claims description 2
- 239000001755 magnesium gluconate Substances 0.000 claims description 2
- 235000015778 magnesium gluconate Nutrition 0.000 claims description 2
- 229960003035 magnesium gluconate Drugs 0.000 claims description 2
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 claims description 2
- 239000011683 manganese gluconate Substances 0.000 claims description 2
- 235000014012 manganese gluconate Nutrition 0.000 claims description 2
- 229940072543 manganese gluconate Drugs 0.000 claims description 2
- OXHQNTSSPHKCPB-IYEMJOQQSA-L manganese(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Mn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OXHQNTSSPHKCPB-IYEMJOQQSA-L 0.000 claims description 2
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 2
- 229960004839 potassium iodide Drugs 0.000 claims description 2
- 235000007715 potassium iodide Nutrition 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 239000001054 red pigment Substances 0.000 claims description 2
- 150000004671 saturated fatty acids Chemical group 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 239000011781 sodium selenite Substances 0.000 claims description 2
- 235000015921 sodium selenite Nutrition 0.000 claims description 2
- 229960001471 sodium selenite Drugs 0.000 claims description 2
- 235000019710 soybean protein Nutrition 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 2
- 235000008939 whole milk Nutrition 0.000 claims description 2
- 239000011670 zinc gluconate Substances 0.000 claims description 2
- 235000011478 zinc gluconate Nutrition 0.000 claims description 2
- 229960000306 zinc gluconate Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 claims 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 240000001949 Taraxacum officinale Species 0.000 claims 1
- 229940108925 copper gluconate Drugs 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 229910052750 molybdenum Inorganic materials 0.000 claims 1
- 239000011733 molybdenum Substances 0.000 claims 1
- 206010003805 Autism Diseases 0.000 abstract description 15
- 208000020706 Autistic disease Diseases 0.000 abstract description 15
- 238000011161 development Methods 0.000 abstract description 12
- 230000012010 growth Effects 0.000 abstract description 6
- 235000015816 nutrient absorption Nutrition 0.000 abstract description 5
- 230000005784 autoimmunity Effects 0.000 abstract description 4
- 230000008506 pathogenesis Effects 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 18
- 230000018109 developmental process Effects 0.000 description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
- 239000011575 calcium Substances 0.000 description 10
- 229960005069 calcium Drugs 0.000 description 10
- 229910052791 calcium Inorganic materials 0.000 description 10
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 9
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 9
- 229910052742 iron Inorganic materials 0.000 description 9
- 239000011777 magnesium Substances 0.000 description 9
- 229910052749 magnesium Inorganic materials 0.000 description 9
- 229940091250 magnesium supplement Drugs 0.000 description 9
- 239000011701 zinc Substances 0.000 description 9
- 229910052725 zinc Inorganic materials 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 241000245665 Taraxacum Species 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- 239000011261 inert gas Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- 241000206575 Chondrus crispus Species 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N D-Maltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 244000082204 Phyllostachys viridis Species 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000002082 anti-convulsion Effects 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000003132 food thickener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000003997 social interaction Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000009999 tuberous sclerosis Diseases 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 101800001144 Arg-vasopressin Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 208000022306 Cerebral injury Diseases 0.000 description 1
- 208000003606 Congenital Rubella Syndrome Diseases 0.000 description 1
- 206010010619 Congenital rubella infection Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000726221 Gemma Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010056254 Intrauterine infection Diseases 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 206010051808 Lymphoid tissue hyperplasia Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 101710203761 Neurexin-1 Proteins 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 108050009621 Synapsin Proteins 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010062233 Uterine infection Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000007416 antiviral immune response Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000021061 dietary behavior Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000020429 malt syrup Nutrition 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008271 nervous system development Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000016839 purine metabolism disease Diseases 0.000 description 1
- 229940026314 red yeast rice Drugs 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004006 stereotypic behavior Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pediatric Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of self-closing disease tailored version clinical nutrition compositions, are grouped as by the group of following weight: 18-26g protein, 0-1g fat, 20-40g carbohydrate, 5-15g dietary fiber, 0.4-0.7g macroelement, 0.1-0.4g microelement, 0.1-0.25g probiotics, natural plants compound 1-2g, 0.5-5g integration of drinking and medicinal herbs ingredient and 0.05-2g new resource food；The present invention also provides the preparation methods of above-mentioned clinical nutrition composition.Clinical nutrition composition of the invention can be alleviated and be improved to the corresponding symptom of self-closing disease from pathogenesis, enhance the autoimmunity of autism children simultaneously, promote autism children normal growth and development and nutrient absorption, to realize its nutrition miscellaneous function on clinical treatment.
Description
Technical field
The present invention relates to clinical nutrition formulation art more particularly to a kind of self-closing disease tailored version clinical nutrition composition and its
Preparation method.
Background technique
Self-closing disease: also known as autism is classified as a kind of developmental disorder as caused by nervous system disorder, symptom packet
Include abnormal sociability, communication capability, interest and behavior pattern.Self-closing disease is a kind of popularity development obstacles, with serious
, the spiritual disease that extensive social interaction and the damage and mechanical behavior of communication skill, interest and activity are characterized
Disease.
Clinical manifestation has: 1 social interactions obstacle, 2 communication obstacles, and 3 repeat stereotypic behavior, and 4 intelligence are abnormal, and 5 feel
It is abnormal, 6 other: it is more it is dynamic, dispersion attention, fly into a rage, attack, feeling sorrow for oneself, 7 solitarily peel off, will not normally be contacted with people's foundation,
8 disfluencys are very prominent, and 9 interest are narrow, the mechanical repetition of behavior, are strongly required environment and remain unchanged, 10 most intellectual developments
It is backward and unbalanced
Modern is summarized as follows the research for the influence factor for causing self-closing disease:
1 inherent cause: the genetics factor of self-closing disease is concentrated mainly on the exception of gene mutation and chromosome, including point is dashed forward
Change, gene copy number variation, desmic region and microRNAs etc., the people with specific heredity or karyological character are easier to suffer from
Self-closing disease, such as fragile X chromosome or tuberous sclerosis.Although gene is a risk factors of self-closing disease, however, at present
The gene for not yet determining self-closing disease only reports some potential susceptible or Disease-causing genes such as synapsin gene etc..In addition it ties
Section property sclerosis gene may with the gene unconventionality is able to detect that in self-closing disease patient, influenced in certain autism children bodies
Mutation, which has occurred, in the topoisomerase related gene of brain development causes expression quantity to reduce, and self-closing disease patient is demonstrated by the something lost of height
It passes heterogeneous, it is however still unclear that these genes are the generations for influencing self-closing disease alone or in combination, if neurexin-1 gene is to maintain
The cell adhesion molecule of spinal animals nervous function and a histone family gene of receptor, may take part in self-closing disease and
Schizoid formation, however large-scale inquiry is not found the exception of relevant coded sequence in autism children body,
And this gene not will lead to self-closing disease individually, it is necessary to be likely to cause self-closing disease together with other factors.According to statistics, greatly
About 3-12 synergistic effect of gene is likely to cause self-closing disease, and these suspicious gene multidigits in No. 2, No. 5, No. 7 and
On No. 16 chromosomes.Although research thinks that self-closing disease is a kind of genetic disease of the controlled by multiple genes of complexity, there is no send out
Existing exact self-closing disease Disease-causing gene, in fact genetics factor can about explain the self-closing disease origin cause of formation of 10-30%, its hair
Sick rate increases rapidly deviate considerably from Hardy-Weinberg equilibrium year by year, and prompting self-closing disease is that heredity and external environment interaction are drawn
The disease risen, and environment may be even more the factor for being worth us to pay close attention to.
2 neural biochemical factors: the critical period of growth course and plasticity are the important contents of neurobiological study.Children
Behavior is closely related with neurotransmitter, it is believed that related to central nervous system 5-HT and (or) dopamine activity decline.Under
Thalamus dysfunction then can produce autism.
3 cognitive defect factors: scholar proposes cognitive function theory relevant to social function, it is believed that psychological cognition lacks
It falls into and compromises Autism children the shortage of social contact ability is caused to the understandability of other people state of mind, or even treat him
People is just as treating abiotic object, others the conscious behavior of normal error understanding
4 environmental factors:
Pregnancy period researchs and proposes pregnant woman and pregnancy complication occurs because being known as, or experience uterine infection, environmental pollution and contact
Chemical substance etc. may all improve the risk that fetus suffers from self-closing disease.
Heavy metal factor:
Other heavy metals such as lead can damage nervous system after entering human body, so as to lead to self-closing disease.
Studies have found that heavy metal and xenobiotics can cause sulphur metabolic disorder, redox is horizontal and methylation all can be by
To influence.
Brain intestines factor: self-closing disease patient generally entails enteron aisle exception, can cause intestinal cell when inflammation occurs in enteron aisle
Swelling, space between cells become larger, and intestines is caused to leak, and cause macromolecular substances that can penetrate intestinal wall and enter in vivo, in addition, serious enteron aisle
Problem may be easier to enter enteron aisle with the breakage and ulcer of enteron aisle, macromolecular substances.The gastrointestinal tract disease of self-closing disease patient
Shape specifically includes that lymph nodular hyperplasia, enterocolitis, gastritis, esophagitis, intestinal permeability increase, disaccharide enzymatic activity not
Foot, the cell factor that lymphocyte population density is higher, abnormal and immunoglobulin etc. and enteric flora disturbance.
5 Different types of etiopathogenises: autism is often existed simultaneously with certain diseases, such as fragile X mental retardation, tuberous sclerosis, myotrophy
Bad, congenital rubella, phenylketonuria and purine metabolism disease etc..And the age of parent both sides is excessive；Psychological factor；It is right
5-HT metabolism, the metabolism of lipid-metabolism and sulfate are bad；It is related to the neuropeptides such as immune factor and arginine vasopressin, it can
See that self-closing disease is the nervous syndrome of kind of multifactor impact.
There is research to confirm that self-closing disease is related with certain element metabolism obstacles, such as iron, calcium indispensable element lack or absorb barrier
Hindering, causes nerve cell to occur in increment atomization abnormal, lead, mercury content cross the eubolism of high interference neurotransmitter,
There is cerebral cortex paradoxical discharge, leads to cerebral injury.The long-term lacking of vitamin D also will increase the morbidity of self-closing disease.
The increase that self-closing disease can be caused to fall ill after nervous system development early stage multi-infection after intrauterine infection and birth, it is such as huge
Cell virus, rubella virus, herpes zoster virus, herpes simplex virus etc..Nineteen ninety has scholar to propose persistent infection theory,
It will continue lays dormant for years in host after thinking virus infection, and lack immune cell clones, to cannot generate antiviral
Immune response finally damages development of central nervous system, leads to the generation of disease.Many autism childrens all merge a kind of or more
Kind autoimmune disease, and all common autoimmune diseases are almost covered, such as autoimmune lymphoid tissue
Hyperplasia syndrome, teenager's systematicness rheumatoid arthritis, systemic loupus erythematosus etc., digest above and below in autism children
The inflammatory reaction in road is also often reported.
Severe dietary behavior problem drastically influences the growth and development of autism children, the hypoevolutism including bone,
And the shortage of chronic vitamin and mineral.
Therefore, develop one kind can fill up at present there has been no specific clinical nutrition products can from pathogenesis to from
The corresponding symptom for closing disease is alleviated and is improved, while enhancing the autoimmunity of autism children, is promoting autism children just
The clinical nutrition formula for being frequently grown development and nutrient absorption has important value and wide market.
Summary of the invention
The technical problems to be solved by the present invention are: in view of the drawbacks of the prior art, a kind of self-closing disease tailored version is provided and is faced
Bed alimentation composition and preparation method thereof, can be alleviated and be improved to the corresponding symptom of self-closing disease from pathogenesis, together
The autoimmunity of Shi Zengqiang sufferer promotes sufferer normal growth and development and nutrient absorption, to realize it on clinical treatment
Nutrition miscellaneous function.
To achieve the above object, the invention adopts the following technical scheme:
The first purpose of the invention is to provide a kind of self-closing disease tailored version clinical nutrition compositions, by the group of following weight
Be grouped as: 18-26g protein, 0-1g fat, 20-40g carbohydrate, 5-15g dietary fiber, 0.4-0.7g macroelement,
0.1-0.4g microelement, 0.1-0.25g probiotics, 0.01-0.05g prebiotics, 1-10g natural pigment, 1-2g natural plants
Compound, 0.5-5g integration of drinking and medicinal herbs ingredient and 0.05-2g new resource food；
Wherein, the integration of drinking and medicinal herbs ingredient include peppermint, Radix Glycyrrhizae, ginger, orange peel, honeysuckle, dandelion, Poria cocos, fructus lycii,
At least one of rhizoma polygonati；
Wherein, the new resource food includes first milk basic protein, γ-aminobutyric acid, chitosan oligosaccharide, eucommia Bark male flower, the leaf of bamboo
Flavones, casein phosphopeptide, avenabeta glucosan, Oligomeric manna sugar, Ribes burejense powder, phosphatidylserine, stachyose, Rosa roxburghii Tratt, ferment
At least one of female beta glucan, newborn mineral salt, pueraria root powder, Rosa roxburghii Tratt, xylo-oligosaccharide.
Further, the protein and amino acid by PURE WHEY, soybean protein isolate, hydrolysis Isin glue collagen,
Whole milk powder, dried whole-egg, lactoferrin, colostrum, L-lysine-Pidolidone, Pidolidone, L-arginine, L-Trp,
L-Glutamine, taurine, Valine, l-Isoleucine, a kind of in L-Leu or at least two compositions.
Further, the natural pigment by astaxanthin, capsicum red pigment, ferroheme, alkermes, lac be red, red yeast rice
A kind of or at least two compositions in pigment.
Further, the fat is by saturated fatty acid, polyunsaturated fatty acid, monounsaturated fatty acids, OPO structure
Rouge, DHA, EPA, ARA, a kind of in phosphatide or at least two compositions.
Further, the carbohydrate by a kind of in fructose, rock sugar, maltodextrin, tapioca, resistant starch or
At least two kinds compositions.
Further, the dietary fiber includes inulin, konjaku flour, galactooligosaccharide, oligofructose, oligomeric different malt
Sugar, soybean polyoses, cyclodextrin, resistant dextrin, a kind of in soybean fiber or at least two compositions.
Further, the macroelement is by calcium citrate, L-calcium lactate, calcium monohydrogen phosphate, ASPARTIC ACID calcium, grape
A kind of in saccharic acid potassium, sodium citrate and magnesium gluconate, several mixing compositions.
Further, the microelement is by ferrous gluconate, potassium iodide, zinc gluconate, sodium selenite, glucose
A kind of in sour copper, chromium sulfate, manganese gluconate and sodium molybdate, several mixing compositions.
Further, the probiotics is made of bacillus, Bifidobacterium, lactic acid bacteria one kind, several mixing.
Further, the prebiotics are made of at least one of bifidus factor and non-digestible glycan.
In order to optimize above-mentioned technical solution, the technical measures that the present invention takes further include:
Ground is advanced optimized, a kind of self-closing disease tailored version clinical nutrition composition is grouped as by the group of following weight:
24-25g protein, 0-1g fat, 25-30g carbohydrate, 5-10g dietary fiber, 0.5-0.6g macroelement, 0.3-
0.4g microelement, 0.22-0.23g probiotics, 0.01-0.02g prebiotics, 2-5g natural pigment, 1.8-2g natural plants
Close object, 0.6-3g integration of drinking and medicinal herbs ingredient and 0.9-1g new resource food；
Ground is advanced optimized, includes hydrolyzing lactoalbumin powder, the soybean of following weight number in the protein and amino acid
Gly-His-Lys, Lyophilized Bovine Colostrums, taurine: 15-20g hydrolyzing lactoalbumin powder, 5-10g soy peptide powder, the freeze-drying of 0.5-1g colostrum
Powder, 0.1-0.15g taurine.
Ground is advanced optimized, include the astaxanthin and monascorubin of following weight number in the natural pigment: 2.5g shrimp is green
Element, 1.5g monascorubin.
Ground is advanced optimized, the carbohydrate includes at least 25-30g maltodextrin.
Ground is advanced optimized, the dietary fiber includes at least 5-10g oligofructose.
Ground is advanced optimized, includes the magnesium and calcium of following weight number: 0.15-0.2g magnesium, 0.3- in the macroelement
0.5g calcium.
Ground is advanced optimized, includes the iron and zinc of following weight number: 0.15-0.2g iron, 0.15- in the microelement
0.2g zinc.
Ground is advanced optimized, includes bacillus, Bifidobacterium, the lactic acid bacteria of following weight number in the probiotics:
0.05g bacillus, 0.05g Bifidobacterium, 0.1g lactic acid bacteria.
Further, the natural plants compound includes at least 1-2g L-carnitine.
Advanced optimize ground, the integration of drinking and medicinal herbs ingredient include the orange peel of following weight number, honeysuckle, dandelion, Poria cocos,
Fructus lycii, rhizoma polygonati: 0.1-0.5g orange peel, 0.1-0.5g honeysuckle, 0.1-0.5g dandelion, 0.1-0.5g Poria cocos, 0.1-0.5g Chinese holly
Qi, 0.1-0.5g rhizoma polygonati.
Further, the new resource food includes the Ribes burejense powder, phosphatidylserine, gamma-amino fourth of following weight number
Acid: 0.01-0.5g Ribes burejense powder, 0.01-0.2g acyl serine, 0.01-0.2g phosphatide γ-aminobutyric acid.
It is further preferred that the prebiotics include the bifidus factor and non-digestible glycan of following weight number: 0.01g is bis-
The non-digestible glycan of the discrimination factor, 0.01g.
A second object of the present invention is to provide a kind of a kind of above-mentioned preparations of self-closing disease tailored version clinical nutrition composition
Method, which comprises the steps of:
Step 1, powdered oil (powder fat) is prepared:
Step 2, integration of drinking and medicinal herbs component powders are prepared: being crushed using raw material of the pulverizer to predetermined weight number, by powder
Broken raw material is placed in container, and 3-8 times of the water that weight is raw material weight is added, and impregnate 3-4 hours, then to soak
Decoction 30-60min is carried out, filtering removal raw material is left and taken decoction liquor, is spray-dried to decoction liquor, with 60-80 mesh point system
Standby integration of drinking and medicinal herbs component powders；
Step 3, by the protein of predetermined weight and amino acid, natural pigment, dietary fiber, microelement, Fruit powder, benefit
Raw bacterium, prebiotics, integration of drinking and medicinal herbs ingredient and new resource food are prepared into the powder that partial size is 150-250 μm respectively；
Step 4, the mixing machine that powder obtained by step 1- step 3 sequentially adds cone-type mixer or other forms is mixed
Uniformly obtained formula mixture is closed, it is spare after sterilization processing；
Step 5, the formula mixture in step 4 is prepared by nutrient powder, nutrition emulsion, capsule according to conventional technical means
At least one of agent, tablet, pill or oral solution.
In order to optimize above-mentioned preparation method, the technical measures that the present invention takes further include:
With advanced optimizing, in step 1, powdered oil (powder fat), preparation method are prepared are as follows:
A) it prepares wall material aqueous solution: taking 36 grams of maltodextrin, malt syrup 9g, casein sodium 3g, 50 milliliters of water stirrings
Uniformly (has ready conditions and heat while stirring to 60 DEG C, be cooled to room temperature after being kept for 30 minutes).
B) 0.1 gram (total solid concentration is 0.2%) is taken uniformly to be dissolved in (purple perilla seed in 20.18 milliliters of greases monoglyceride
20 milliliters of oil, vitamin E 0.1g, single 0.08 milliliter of diglycerine fatty acid ester).
C) 0.1 gram (total solid concentration is 0.2%) is taken uniformly to be dissolved in wall material aqueous solution Tween 80.
D) the wall material aqueous solution of the mixed plant grease and addition Over emulsfication agent Tween 80 of Over emulsfication agent monoglyceride will be added
It is sufficiently mixed.
E) addition stabilizer agar takes 0.1 gram (total solid concentration be 0.2%) into after mixed solution, is settled to water
200 milliliters (total solid concentration be 25%), high speed dispersion 2 minutes under 20000r/min.
F) homogenization pressure is 25MPa, and homogeneous 3 times (every time 5 minutes), homogeneous emulsion is made.
G) emulsion obtained is spray-dried, inlet air temperature is 195 DEG C, and leaving air temp is 80 DEG C.Collect powder
Grease (powder fat).
Ground is advanced optimized, in step 2, the method for preparing integration of drinking and medicinal herbs component powders are as follows: using pulverizer to predetermined weight
The raw material of amount number is crushed, and the raw material of crushing is placed in container, and 3-8 times of the water that weight is raw material weight is added, carries out
It impregnates 3-4 hours, decoction 30-60min then is carried out to soak, filtering removal raw material is left and taken decoction liquor, carried out to decoction liquor
Spray drying prepares integration of drinking and medicinal herbs component powders with 60-80 mesh point.
With advanced optimizing, in step 5, optionally increase suitable food thickening agent and food additives.It is described
Food thickening agent be guar gum, xanthan gum, locust bean gum, konjac glucomannan, pectin, carragheen, agar, gelatin, in Arabic gum extremely
Few one kind, the food additives are at least one of Aspartame, edible essence fragrance, brown sugar；More preferable carragheen, Ah
Draw primary glue, guar gum, Aspartame, edible essence fragrance.
Ground is advanced optimized, a kind of above-mentioned operating procedure of the preparation method of self-closing disease tailored version clinical nutrition composition is equal
It need to be carried out under the protection of inert gas, used inert gas is nitrogen, argon gas, helium etc..In the protection of inert gas
The lower aforesaid operations step that carries out can prevent the danger of powder explosion.
Ground is advanced optimized, can be prepared into the classes such as powdery, graininess, capsule shape, tablet shape, beverage according to the formula
Not.
The present invention by adopting the above technical scheme, compared with prior art, has the following technical effect that
1) add 0.1-0.2g γ-aminobutyric acid: γ-aminobutyric acid has calmness, hypnosis, anticonvulsion, blood pressure lowering life
Reason effect, and have the function of promoting animal gastric juice and growth hormone secretion.
2) add 0.1-0.2g phosphatidylserine: phosphatidylserine function mainly improves nerve cell function, adjusts
The conduction of nerve impulse is saved, blood can be run through by promoting brain memory function since it is with very strong lipophilicity after absorption
Brain barrier enters brain, plays the role of vascular smooth muscle cells of releiving, and increases brain blood supply.
3) add 2.5g astaxanthin, astaxanthin can across barrier from blood to brain, so astaxanthin to brain, in
Pivot nervous system and eyes can all play a protective role.
4) 1.5g monascorubin is added, there is stronger inhibiting effect to bacillus subtilis, staphylococcus aureus, it can
It improves the immunity of the human body.
5) add 0.1-0.5g fructus lycii: fructus lycii has enhancing nospecific immunity effect, improves disease resistance, inhibits tumour
Growth and cell mutation.Fructus lycii is obviously promoted hematopoietic cell proliferation, leukocyte count can be made to increase, enhance human body
Hematopoiesis function.
6) addition includes the macroelement of magnesium: such macroelement has promotion cardiovascular health, prevents calcium in tissue and blood
The effect deposited in pipe, is resistant to hypochondriacal natural sedative.
7) addition includes the microelement of zinc: taste and smell can be improved in such microelement, increases appetite, promotes wound
The healing of mouth and wound, strengthen immunity being capable of enhancing development and intellectual development.
8) add 0.05g Bifidobacterium: Bifidobacterium has biological barrier, trophism, antitumor work to human health
With, immunological enhancement, improve a variety of important physiological functions such as gastrointestinal function, anti-aging.
9) bifidus factor, bifidus factor can activate Bifidobacterium in enteron aisle and promote its growth and breeding.
The present invention is plain by selecting the basal nutrient of rational proportion, while adding to have and promote nutrient absorption and calmness, urge
It sleeps, is anticonvulsion, protection nerve cell, reducing blood pressure, enhance nospecific immunity effect, enhancing development and intellectual development
The special dietaries substance such as integration of drinking and medicinal herbs ingredient and new resource food, and adjust its proportion and carry out compatibility increasing with basal nutrient element
Effect, a kind of self-closing disease tailored version clinical nutrition composition of the invention enable is from pathogenesis to the corresponding disease of self-closing disease
Shape is alleviated and is improved, while enhancing the autoimmunity of autism children, promote autism children normal growth and development and
Nutrient absorption, to realize its nutrition miscellaneous function on clinical treatment.
Specific embodiment
The present invention provides a kind of self-closing disease tailored version clinical nutrition compositions, are grouped as by the group of following weight: 18-
26g protein, 0-1g fat, 20-40g carbohydrate, 5-15g dietary fiber, 0.4-0.7g macroelement, 0.1-0.4g are micro-
Secondary element, 0.1-0.25g probiotics, 0.01-0.05g prebiotics, 1-10g natural pigment, 1-2g natural plants compound, 0.5-
5g integration of drinking and medicinal herbs ingredient and 0.05-2g new resource food；
Wherein, the integration of drinking and medicinal herbs ingredient include peppermint, Radix Glycyrrhizae, ginger, orange peel, honeysuckle, dandelion, Poria cocos, fructus lycii,
Rhizoma polygonati is a kind of or at least two form；
Wherein, the new resource food includes first milk basic protein, γ-aminobutyric acid, chitosan oligosaccharide, eucommia Bark male flower, the leaf of bamboo
Flavones, casein phosphopeptide, avenabeta glucosan, Oligomeric manna sugar, Ribes burejense powder, phosphatidylserine, stachyose, Rosa roxburghii Tratt, ferment
Female beta glucan, newborn mineral salt, pueraria root powder, Rosa roxburghii Tratt, xylo-oligosaccharide are a kind of or at least two form.
The present invention is described in more detail below by specific embodiment, for a better understanding of the present invention,
But following embodiments are not intended to limit the scope of the invention.
Embodiment 1
A kind of self-closing disease tailored version clinical nutrition composition of the present invention includes maltodextrin 25.8g, hydrolyzed whey
Albumen powder 18g, oligofructose 5g, soy peptide powder 6g, 2.5g astaxanthin, 1.5g monascorubin, L-carnitine 1.8g, colostrum freeze
Dry powder 0.6g, orange peel 0.5g, honeysuckle 0.5g, dandelion 0.5g, Poria cocos 0.5g, fructus lycii 0.5g, rhizoma polygonati 0.5g, Ribes burejense powder
0.5g, phosphatidylserine 0.2g, γ-aminobutyric acid 0.2g, taurine 0.12g, magnesium 0.16g, calcium 0.36g, iron 0.17g, zinc
0.16g, 0.05g bacillus, 0.05g Bifidobacterium, 0.1g lactic acid bacteria, 0.01g bifidus factor, the non-digestible glycan of 0.01g.
Embodiment 2
A kind of self-closing disease tailored version clinical nutrition composition of the present invention includes maltodextrin 28.2g, hydrolyzed whey
Albumen powder 18g, oligofructose 5g, soy peptide powder 6g, 2.5g astaxanthin, 1.5g monascorubin, L-carnitine 1.8g, colostrum freeze
Dry powder 0.6g, orange peel 0.1g, honeysuckle 0.1g, dandelion 0.1g, Poria cocos 0.1g, fructus lycii 0.1g, rhizoma polygonati 0.1g, Ribes burejense powder
0.5g, phosphatidylserine 0.2g, γ-aminobutyric acid 0.2g, taurine 0.12g, magnesium 0.16g, calcium 0.36g, iron 0.17g, zinc
0.16g, 0.05g bacillus, 0.05g Bifidobacterium, 0.1g lactic acid bacteria, 0.01g bifidus factor, the non-digestible glycan of 0.01g.
Embodiment 3
A kind of self-closing disease tailored version clinical nutrition composition of the present invention includes maltodextrin 29g, hydrolyzed whey egg
White powder 18g, oligofructose 5g, soy peptide powder 6g, 2.5g astaxanthin, 1.5g monascorubin, L-carnitine 1.8g, colostrum freeze-drying
Powder 0.6g, orange peel 0.1g, honeysuckle 0.1g, dandelion 0.1g, Poria cocos 0.1g, fructus lycii 0.1g, rhizoma polygonati 0.1g, Ribes burejense powder 0.01g,
Phosphatidylserine 0.01g, γ-aminobutyric acid 0.01g, taurine 0.12g, magnesium 0.16g, calcium 0.36g, iron 0.17g, zinc
0.16g, 0.05g bacillus, 0.05g Bifidobacterium, 0.1g lactic acid bacteria, 0.01g bifidus factor, the non-digestible glycan of 0.01g.
Embodiment 4
A kind of self-closing disease tailored version clinical nutrition composition of the present invention includes fructose 25g, hydrolyzing lactoalbumin powder
20g, inulin 5g, soy peptide powder 6g, 2g astaxanthin, 1g monascorubin, L-carnitine 1.8g, Lyophilized Bovine Colostrums 0.6g, peppermint
0.5g, Radix Glycyrrhizae 0.5g, ginger 0.5g, Poria cocos 0.5g, fructus lycii 0.5g, rhizoma polygonati 0.5g, Ribes burejense powder 0.5g, phosphatidylserine
0.2g, γ-aminobutyric acid 0.2g, taurine 0.12g, magnesium 0.16g, calcium 0.36g, iron 0.17g, zinc 0.16g, 0.01g gemma bar
Bacterium, 0.01g Bifidobacterium, 0.08g lactic acid bacteria, 0.01g bifidus factor, the non-digestible glycan of 0.01g.
Embodiment 5
A kind of self-closing disease tailored version clinical nutrition composition of the present invention includes rock sugar 28g, hydrolyzing lactoalbumin powder
19g, konjaku flour 10g, soy peptide powder 7g, 0.5g astaxanthin, 0.1g monascorubin, L-carnitine 1.8g, Lyophilized Bovine Colostrums
0.6g, peppermint 0.2g, Radix Glycyrrhizae 0.2g, ginger 0.2g, Poria cocos 0.2g, fructus lycii 0.2g, rhizoma polygonati 0.2g, Ribes burejense powder 0.5g, phosphatidyl
Serine 0.2g, γ-aminobutyric acid 0.2g, taurine 0.12g, magnesium 0.16g, calcium 0.36g, iron 0.17g, zinc 0.16g,
0.0125g bacillus, 0.0125g Bifidobacterium, 0.2g lactic acid bacteria, 0.01g bifidus factor, the non-digestible glycan of 0.01g.
Embodiment 6
A kind of self-closing disease tailored version clinical nutrition composition of the present invention includes resistant starch 30g, hydrolyzed whey egg
White powder 15g, resistant dextrin 15g, soy peptide powder 3g, 5g astaxanthin, 3g monascorubin, L-carnitine 1.8g, Lyophilized Bovine Colostrums
0.6g, peppermint 0.5g, Radix Glycyrrhizae 0.5g, ginger 0.5g, Poria cocos 0.5g, fructus lycii 0.5g, rhizoma polygonati 0.5g, Ribes burejense powder 0.01g, phosphatidyl
Serine 0.01g, γ-aminobutyric acid 0.01g, taurine 0.12g, magnesium 0.16g, calcium 0.36g, iron 0.17g, zinc 0.16g, 0.2g
Bifidobacterium, 0.01g bifidus factor, the non-digestible glycan of 0.01g.
Specific embodiments of the present invention are described in detail above, but it is merely an example, the present invention is simultaneously unlimited
It is formed on particular embodiments described above.To those skilled in the art, any couple of present invention carries out equivalent modifications and
Substitution is also all among scope of the invention.Therefore, without departing from the spirit and scope of the invention made by equal transformation and
Modification, all should be contained within the scope of the invention.
Claims (12)
1. a kind of self-closing disease tailored version clinical nutrition composition, is grouped as by the group of following weight: 18-26g protein, 0-1g rouge
Fat, 20-40g carbohydrate, 5-15g dietary fiber, 0.4-0.7g macroelement, 0.1-0.4g microelement, 0.1-0.25g
Probiotics, 0.01-0.05g prebiotics, 1-10g natural pigment, 1-2g natural plants compound, 0.5-5g integration of drinking and medicinal herbs ingredient with
And 0.05-2g new resource food；
Wherein, the integration of drinking and medicinal herbs ingredient includes peppermint, Radix Glycyrrhizae, ginger, orange peel, honeysuckle, dandelion, Poria cocos, fructus lycii, rhizoma polygonati
A kind of or at least two compositions；
Wherein, the new resource food include first milk basic protein, γ-aminobutyric acid, chitosan oligosaccharide, eucommia Bark male flower, bamboo-leaves flavones,
Casein phosphopeptide, avenabeta glucosan, Oligomeric manna sugar, Ribes burejense powder, phosphatidylserine, stachyose, Rosa roxburghii Tratt, yeast β-Portugal
Glycan, newborn mineral salt, pueraria root powder, Rosa roxburghii Tratt, xylo-oligosaccharide are a kind of or at least two form.
2. a kind of self-closing disease tailored version clinical nutrition composition according to claim 1, which is characterized in that the protein
With amino acid by PURE WHEY, soybean protein isolate, hydrolysis Isin glue collagen, whole milk powder, dried whole-egg, lactoferrin, ox
Colostrum, L-lysine-Pidolidone, Pidolidone, L-arginine, L-Trp, L-Glutamine, taurine, Valine,
A kind of or at least two compositions in l-Isoleucine, L-Leu.
3. a kind of self-closing disease tailored version clinical nutrition composition according to claim 1, which is characterized in that the natural colour
Element is by astaxanthin, capsicum red pigment, ferroheme, alkermes, lac are red, a kind of in monascorubin or at least two form.
4. a kind of self-closing disease tailored version clinical nutrition composition according to claim 1, which is characterized in that it is described fat by
It is saturated fatty acid, polyunsaturated fatty acid, monounsaturated fatty acids, OPO structured lipid, DHA, EPA, ARA, a kind of in phosphatide or extremely
Few two kinds of compositions.
5. a kind of self-closing disease tailored version clinical nutrition composition according to claim 1, which is characterized in that the carbon aquation
Object is closed by a kind of in fructose, rock sugar, maltodextrin, tapioca, resistant starch or at least two kinds form.
6. a kind of self-closing disease tailored version clinical nutrition composition according to claim 1, which is characterized in that the diet is fine
Dimension comprising inulin, konjaku flour, galactooligosaccharide, oligofructose, oligoisomaltose, soybean polyoses, cyclodextrin, resistant dextrin,
A kind of or at least two compositions in soybean fiber.
7. a kind of self-closing disease tailored version clinical nutrition composition according to claim 1, which is characterized in that the constant member
Element is by calcium citrate, L-calcium lactate, calcium monohydrogen phosphate, ASPARTIC ACID calcium, K-IAO, sodium citrate and magnesium gluconate
Middle a kind of, several mixing composition.
8. a kind of self-closing disease tailored version clinical nutrition composition according to claim 1, which is characterized in that the micro member
Element is by ferrous gluconate, potassium iodide, zinc gluconate, sodium selenite, copper gluconate, chromium sulfate, manganese gluconate and molybdenum
A kind of in sour sodium, several mixing compositions.
9. a kind of self-closing disease tailored version clinical nutrition composition according to claim 1, which is characterized in that the probiotics
It is made of bacillus, Bifidobacterium, lactic acid bacteria one kind, several mixing.
10. a kind of self-closing disease tailored version clinical nutrition composition according to claim 1, which is characterized in that described natural
Plant compound is L-carnitine.
11. a kind of self-closing disease tailored version clinical nutrition composition according to claim 1, which is characterized in that described prebiotic
Member is made of at least one of bifidus factor and non-digestible glycan.
12. a kind of such as a kind of preparation side of self-closing disease tailored version clinical nutrition composition of any of claims 1-11
Method, which comprises the steps of:
Step 1, powdered oil is prepared；
Step 2, integration of drinking and medicinal herbs component powders are prepared: being crushed using raw material of the pulverizer to predetermined weight number, by crushing
Raw material is placed in container, and 3-8 times of the water that weight is raw material weight is added, and impregnate 3-4 hours, is then carried out to soak
30-60min is decocted, filtering removal raw material is left and taken decoction liquor, is spray-dried to decoction liquor, prepares medicine with 60-80 mesh point
Eat homologous component powders；
Step 3, the protein of predetermined weight and amino acid, natural pigment, dietary fiber, microelement, lactic acid bacteria, medicine are eaten same
Derived components and new resource food are prepared into the powder that partial size is 150-250 μm respectively；
Step 4, the mixing machine that powder obtained by step 1- step 3 sequentially adds cone-type mixer or other forms is mixed
Even obtained formula mixture, it is spare after sterilization processing；
Step 5, according to conventional technical means by the formula mixture in step 4 be prepared into nutrient powder, nutrition emulsion, capsule,
At least one of tablet, pill or oral solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811361341.6A CN109497520A (en) | 2018-11-15 | 2018-11-15 | A kind of self-closing disease tailored version clinical nutrition composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811361341.6A CN109497520A (en) | 2018-11-15 | 2018-11-15 | A kind of self-closing disease tailored version clinical nutrition composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109497520A true CN109497520A (en) | 2019-03-22 |
Family
ID=65748694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811361341.6A Pending CN109497520A (en) | 2018-11-15 | 2018-11-15 | A kind of self-closing disease tailored version clinical nutrition composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109497520A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110720512A (en) * | 2019-11-19 | 2020-01-24 | 江南大学 | Application of CCFM16 in preparation of fungicide, food or medicine for relieving autism and adsorbing polychlorinated biphenyl |
| CN110916192A (en) * | 2019-11-25 | 2020-03-27 | 垒途智能教科技术研究院江苏有限公司 | Probiotic mineral powder capable of preventing and treating autism of children and teenagers and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106858620A (en) * | 2017-03-29 | 2017-06-20 | 上海奥医生物医药科技有限公司 | A kind of anaemia tailored version clinical nutrition formula and preparation method thereof |
| CN107616490A (en) * | 2017-08-23 | 2018-01-23 | 上海奥医生物医药科技有限公司 | A kind of postoperative tailored version clinical nutrition formula of children and preparation method thereof |
| CN108013454A (en) * | 2017-12-13 | 2018-05-11 | 上海奥医生物医药科技有限公司 | Gynaecological imflammation tailored version clinical nutrition formula and preparation method thereof |
| CN108013453A (en) * | 2017-12-13 | 2018-05-11 | 上海奥医生物医药科技有限公司 | Children's lactose intolerance tailored version clinical nutrition formula and preparation method thereof |
| CN108013452A (en) * | 2017-12-13 | 2018-05-11 | 上海奥医生物医药科技有限公司 | A kind of puerperal abdominal flatulence gas tailored version clinical nutrition formula and preparation method thereof |
| CN108077911A (en) * | 2017-12-13 | 2018-05-29 | 上海奥医生物医药科技有限公司 | A kind of epileptic's tailored version clinical nutrition formula and preparation method thereof |
| CN108651988A (en) * | 2018-05-10 | 2018-10-16 | 上海奥医生物医药科技有限公司 | Nephrosis dialysis tailored version clinical nutrition formula and preparation method thereof |
-
2018
- 2018-11-15 CN CN201811361341.6A patent/CN109497520A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106858620A (en) * | 2017-03-29 | 2017-06-20 | 上海奥医生物医药科技有限公司 | A kind of anaemia tailored version clinical nutrition formula and preparation method thereof |
| CN107616490A (en) * | 2017-08-23 | 2018-01-23 | 上海奥医生物医药科技有限公司 | A kind of postoperative tailored version clinical nutrition formula of children and preparation method thereof |
| CN108013454A (en) * | 2017-12-13 | 2018-05-11 | 上海奥医生物医药科技有限公司 | Gynaecological imflammation tailored version clinical nutrition formula and preparation method thereof |
| CN108013453A (en) * | 2017-12-13 | 2018-05-11 | 上海奥医生物医药科技有限公司 | Children's lactose intolerance tailored version clinical nutrition formula and preparation method thereof |
| CN108013452A (en) * | 2017-12-13 | 2018-05-11 | 上海奥医生物医药科技有限公司 | A kind of puerperal abdominal flatulence gas tailored version clinical nutrition formula and preparation method thereof |
| CN108077911A (en) * | 2017-12-13 | 2018-05-29 | 上海奥医生物医药科技有限公司 | A kind of epileptic's tailored version clinical nutrition formula and preparation method thereof |
| CN108651988A (en) * | 2018-05-10 | 2018-10-16 | 上海奥医生物医药科技有限公司 | Nephrosis dialysis tailored version clinical nutrition formula and preparation method thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110720512A (en) * | 2019-11-19 | 2020-01-24 | 江南大学 | Application of CCFM16 in preparation of fungicide, food or medicine for relieving autism and adsorbing polychlorinated biphenyl |
| CN110916192A (en) * | 2019-11-25 | 2020-03-27 | 垒途智能教科技术研究院江苏有限公司 | Probiotic mineral powder capable of preventing and treating autism of children and teenagers and application thereof |
| CN110916192B (en) * | 2019-11-25 | 2021-04-13 | 垒途智能教科技术研究院江苏有限公司 | Probiotic mineral powder capable of preventing and treating autism of children and teenagers and application thereof |
| WO2021102910A1 (en) * | 2019-11-25 | 2021-06-03 | 垒途智能教科技术研究院江苏有限公司 | Probiotic mineral powder capable of preventing and treating infantile autism of children and adolescents, and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69916319T2 (en) | OLIGOSACCHARIDE AND PROBIOTICA CONTAINING PREPARATION | |
| EP4042881A1 (en) | Microcapsule, preparation method and application thereof | |
| CN115024365A (en) | Application of fullerene to preparation of fullerene microcapsule powder and preparation method | |
| CN107319525A (en) | One kind fat-reducing fat reducing tailored version clinical nutrition formula and preparation method thereof | |
| CN107242550A (en) | A kind of male sterility tailored version clinical nutrition formula and preparation method thereof | |
| CN106962912A (en) | A kind of hepatopathy tailored version clinical nutrition formula and preparation method thereof | |
| CN104822279A (en) | Human milk oligosaccharides to ameliorate symptoms of stress | |
| CN106942748A (en) | A kind of female acyesis tailored version clinical nutrition formula and preparation method thereof | |
| CN108651988A (en) | Nephrosis dialysis tailored version clinical nutrition formula and preparation method thereof | |
| CN104219968A (en) | Probiotic derived non-viable material for infection prevention and treatment | |
| CN104783124A (en) | Probiotic table salt and preparing method thereof | |
| CN108077911A (en) | A kind of epileptic's tailored version clinical nutrition formula and preparation method thereof | |
| CN104783028A (en) | A probiotic and a processing method thereof | |
| CN112021564B (en) | Composition for curing stomach and intestine as well as preparation method and application thereof | |
| CN110074397A (en) | A kind of upgrowth and development of children tailored version clinical nutrition formula and preparation method thereof | |
| CN108703365A (en) | Protein allergy tailored version clinical nutrition formula and preparation method thereof | |
| CN108013452A (en) | A kind of puerperal abdominal flatulence gas tailored version clinical nutrition formula and preparation method thereof | |
| JP2007061058A (en) | Immunity reinforcement food containing sugar chain nutrient and method for producing the same | |
| CN113499401A (en) | Pharmaceutical composition for treating Alzheimer disease and preparation method and application thereof | |
| CN109497520A (en) | A kind of self-closing disease tailored version clinical nutrition composition and preparation method thereof | |
| Biswal et al. | Current trends and future prospective of prebiotics as therapeutic food | |
| CN109965271A (en) | A kind of children's brain growth tailored version clinical nutrition formula and preparation method thereof | |
| CN114271335A (en) | Dairy product and method for producing the same | |
| CN109965272A (en) | A kind of children's lead discharging tailored version clinical nutrition formula and preparation method thereof | |
| CN108260802A (en) | A kind of gerontal patient's tailored version clinical nutrition formula and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190322 |